Nanologica AB (publ) (NICA.ST)
SEK 1.71
(-0.58%)
SEK 1.71
(-0.58%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -9.38 Million SEK | 85.7% |
| 2022 | -65.63 Million SEK | -5387.46% |
| 2021 | -1.19 Million SEK | 97.76% |
| 2020 | -53.4 Million SEK | -761.88% |
| 2019 | 8.06 Million SEK | 147.17% |
| 2018 | -17.1 Million SEK | -233.41% |
| 2017 | 12.82 Million SEK | 205.25% |
| 2016 | -12.18 Million SEK | 30.45% |
| 2015 | -17.51 Million SEK | -99.01% |
| 2014 | -8.8 Million SEK | -45.82% |
| 2013 | -6.03 Million SEK | -1190.43% |
| 2012 | -467.7 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -21.46 Million SEK | -128.66% |
| 2024 Q2 | -13.83 Million SEK | 35.57% |
| 2023 Q1 | -52.61 Million SEK | 19.84% |
| 2023 Q3 | -21.38 Million SEK | 36.6% |
| 2023 Q2 | -33.73 Million SEK | 35.88% |
| 2023 Q4 | -9.38 Million SEK | 56.1% |
| 2023 FY | -9.38 Million SEK | 85.7% |
| 2022 Q1 | 4.46 Million SEK | 473.66% |
| 2022 Q4 | -65.63 Million SEK | -560.56% |
| 2022 FY | -65.63 Million SEK | -5387.46% |
| 2022 Q3 | 14.25 Million SEK | 216.05% |
| 2022 Q2 | -12.27 Million SEK | -374.76% |
| 2021 Q1 | -45.3 Million SEK | 15.16% |
| 2021 Q4 | -1.19 Million SEK | 93.16% |
| 2021 Q3 | -17.49 Million SEK | 45.9% |
| 2021 FY | -1.19 Million SEK | 97.76% |
| 2021 Q2 | -32.33 Million SEK | 28.63% |
| 2020 Q4 | -53.4 Million SEK | 28.8% |
| 2020 Q3 | -75 Million SEK | 8.63% |
| 2020 Q2 | -82.08 Million SEK | -1225.85% |
| 2020 FY | -53.4 Million SEK | -761.88% |
| 2020 Q1 | 7.29 Million SEK | -9.63% |
| 2019 Q3 | 4.76 Million SEK | 173.03% |
| 2019 FY | 8.06 Million SEK | 147.17% |
| 2019 Q4 | 8.06 Million SEK | 69.36% |
| 2019 Q2 | -6.52 Million SEK | 50.5% |
| 2019 Q1 | -13.17 Million SEK | 22.95% |
| 2018 Q4 | -17.1 Million SEK | 3.94% |
| 2018 FY | -17.1 Million SEK | -233.41% |
| 2018 Q3 | -17.8 Million SEK | 22.2% |
| 2018 Q2 | -22.88 Million SEK | -235.59% |
| 2018 Q1 | 16.87 Million SEK | 31.65% |
| 2017 FY | 12.82 Million SEK | 205.25% |
| 2017 Q1 | -7.01 Million SEK | 42.41% |
| 2017 Q4 | 12.82 Million SEK | 102.37% |
| 2017 Q2 | -35 Thousand SEK | 99.5% |
| 2017 Q3 | 6.33 Million SEK | 18200.0% |
| 2016 Q2 | -6.44 Million SEK | 48.02% |
| 2016 Q3 | 526 Thousand SEK | 108.16% |
| 2016 FY | -12.18 Million SEK | 30.45% |
| 2016 Q1 | -12.4 Million SEK | 29.18% |
| 2016 Q4 | -12.18 Million SEK | -2415.67% |
| 2015 Q4 | -17.51 Million SEK | 0.0% |
| 2015 Q1 | 9.12 Million SEK | 224.22% |
| 2015 Q2 | -370.99 Thousand SEK | -104.07% |
| 2015 FY | -17.51 Million SEK | -99.01% |
| 2014 FY | -8.8 Million SEK | -45.82% |
| 2014 Q3 | -7.34 Million SEK | 0.0% |
| 2014 Q4 | -7.34 Million SEK | 0.0% |
| 2013 FY | -6.03 Million SEK | -1190.43% |
| 2012 FY | -467.7 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 81.232% |
| Ziccum AB (publ) | -2.13 Million SEK | -339.307% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 50.745% |
| BioArctic AB (publ) | -606.58 Million SEK | 98.452% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 81.199% |
| Mendus AB (publ) | -96.29 Million SEK | 90.251% |
| Genovis AB (publ.) | -43.94 Million SEK | 78.635% |
| Intervacc AB (publ) | -88.16 Million SEK | 89.351% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 145.773% |
| Active Biotech AB (publ) | -33.2 Million SEK | 71.723% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 117.639% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 76.162% |
| Aptahem AB (publ) | 2.9 Million SEK | 422.762% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 97.186% |
| Kancera AB (publ) | -45.69 Million SEK | 79.454% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 97.147% |
| Fluicell AB (publ) | -2.76 Million SEK | -239.776% |
| Saniona AB (publ) | 40.44 Million SEK | 123.211% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 70.595% |
| Biovica International AB (publ) | -58.73 Million SEK | 84.017% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 79.238% |
| AcouSort AB (publ) | -23.98 Million SEK | 60.861% |
| Xintela AB (publ) | -7.8 Million SEK | -20.22% |
| Abliva AB (publ) | -57.24 Million SEK | 83.599% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 95.178% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 88.579% |
| OncoZenge AB (publ) | -12.62 Million SEK | 25.651% |
| Amniotics AB (publ) | -5.63 Million SEK | -66.69% |
| 2cureX AB (publ) | -13.4 Million SEK | 29.956% |
| CombiGene AB (publ) | -101.44 Million SEK | 90.745% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -334.429% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 273.852% |
| Camurus AB (publ) | -1.16 Billion SEK | 99.194% |
| Corline Biomedical AB | -17.01 Million SEK | 44.815% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 88.79% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 93.204% |
| I-Tech AB | -83.26 Million SEK | 88.725% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 106.969% |
| Cyxone AB (publ) | -16.67 Million SEK | 43.683% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 83.202% |
| Biosergen AB | -1.88 Million SEK | -398.566% |
| Cantargia AB (publ) | -139.74 Million SEK | 93.282% |
| NextCell Pharma AB | -46.79 Million SEK | 79.936% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 92.75% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 68.05% |
| SynAct Pharma AB | -61.75 Million SEK | 84.799% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 56.162% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | 29.036% |
| LIDDS AB (publ) | -13.51 Million SEK | 30.521% |
| Lipum AB (publ) | -8.46 Million SEK | -10.904% |
| BioInvent International AB (publ) | -236.3 Million SEK | 96.027% |
| Alzinova AB (publ) | -21.22 Million SEK | 55.771% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 85.971% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -81.203% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 88.789% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -917.118% |
| Simris Alg AB (publ) | 85.07 Million SEK | 111.035% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 88.563% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 105.653% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 54.85% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -215.882% |